The authors proposed retinal microangiopathy as an in vivo biomarker of systemic acute vascular disease and attributed these changes in COVID-19 to the expression of angiotensin-converting enzyme 2 (ACE2) receptor in the retina. This evidence concerns the gene ACE2 and COVID-19.